Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. CGRP and migraine; from bench to bedside

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Exercise training in metabolic myopathies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Neuropathies optiques héréditaires

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Migraine

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. The chronobiology of migraine: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Migraine is ranked as a leading cause of years lived with disability among all neurological disorders. Therapies targeting the calcitonin gene-related peptide (CGRP) signaling pathway, including monoclonal antibodies against the receptor or ligand and small molecule CGRP receptor antagonists (gepants), are today approved for migraine prophylaxis with additional compounds expected to be introduced to the market soon. In this review, we consider other putative prophylactic migraine drugs in development, including compounds targeting G-protein coupled receptors, glutamate, ion channels, and neuromodulatory devices. Emergence of these new interventions could complement our current treatment armamentarium for migraine management.

OriginalsprogEngelsk
TidsskriftRevue Neurologique
Vol/bind177
Udgave nummer7
Sider (fra-til)827-833
Antal sider7
ISSN0035-3787
DOI
StatusUdgivet - sep. 2021

Bibliografisk note

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

ID: 67851018